
Pfizer reported mixed quarterly figures. The company’s waiting for the independent monitor to approve its potential COVID-19 vaccine
After it announced the lengths that will go to in order to have the proper conditions to distribute its potential COVID-19 vaccine, Pfizer made public its Q3 earnings.
The New York-based company reported earnings per share of 0.72 cents on revenue of $12.13 billion. While the EPS came higher than the 0.69 cents expected, the revenue fell short of the $12.31 billion mark.
Along with the Q3 figures came other news. According to Pfizer’s statement, the company’s not ready to go public with the data it collected during the late-stage trials of its potential COVID-19 vaccine that it’s developing alongside Germany’s BioNTech. Pfizer said that the independent monitor hadn’t conducted an in-depth analysis to show whether the drug was efficient.
Since the beginning of the year, the company’s stock price fell 3%, while USA500 gained 4.45%.
Read here more about Pfizer!
Sources: investing.com, reuters.com
Gli utenti / lettori non dovrebbero fare affidamento esclusivamente sulle informazioni qui presentate e dovrebbero fare le proprie ricerche / analisi anche leggendo la ricerca reale sottostante. Il contenuto è generico e non tiene conto di circostanze personali individuali, esperienza di investimento o situazione finanziaria attuale.
Pertanto, Key Way Investments Ltd non accetta alcuna responsabilità per eventuali perdite di trader a causa dell'uso e del contenuto delle informazioni presentate nel presente documento. Le prestazioni passate e le previsioni non sono un indicatore affidabile dei risultati futuri.